Hemostasis initiates angiogenesis-dependent wound healing, and thrombosis is frequently associated with advanced cancer. Although activation of coagulation generates potent regulators of angiogenesis, little is known about how this pathway supports angiogenesis in vivo. Here we show that the tissue factor (TF)-VIIa protease complex, independent of triggering coagulation, can promote tumor and developmental angiogenesis through protease-activated receptor-2 (PAR-2) signaling. In this context, the TF cytoplasmic domain negatively regulates PAR-2 signaling. Mice from which the TF cytoplasmic domain has been deleted (TF∆CT mice) show enhanced PAR-2-dependent angiogenesis, in synergy with platelet-derived growth factor BB (PDGF-BB). Ocular tissue from diabetic patients shows PAR-2 colocalization with phosphorylated TF specifically on neovasculature, suggesting that phosphorylation of the TF cytoplasmic domain releases its negative regulatory control of PAR-2 signaling in angiogenesis. Targeting the TF-VIIa signaling pathway may thus enhance the efficacy of angiostatic treatments for cancer and neovascular eye diseases.
Angiogenesis, the formation of new vessels from pre-existing vasculature, has a crucial role during normal development, tissue regeneration in wound healing and postischemic tissue repair. Neovascularization during tumor expansion and in ischemic retinopathies is an example of angiogenesis-driven disease progression 1, 2 . An increased understanding of the basic mechanisms that regulate physiological and pathological angiogenesis will aid the development of efficient pro-and antiangiogenic therapies 3, 4 . TF initiates the coagulation protease cascade that generates proteolytic fragments with potent regulatory effects on angiogenesis 5 . TF acts as an extracellular coreceptor that activates and presents coagulation proteases for signaling through G-protein-coupled PARs 6 . The PARs are activated through a unique mechanism that involves extracellular proteolysis of the receptor 7, 8 . The TF-VIIa complex, as well as Xa, activate PAR-2 in vitro. Xa can also cleave PAR-1, the first identified thrombin receptor. Xa signals most efficiently in the ternary TF-VIIa-Xa complex 9, 10 .
In vitro data suggest that TF acts as a coreceptor in PAR signaling, but the role of the TF cytoplasmic domain in PAR signaling in vivo remains poorly defined. TF expressed by tumor cells contributes to tumor progression. Upregulation of vascular endothelial cell growth factor (VEGF) by the TF cytoplasmic domain has been suggested 11 , although not widely confirmed 12 , to contribute to pathological angiogenesis. In addition, TF localizes to the endothelium in malignant breast cancer 13 , and direct inhibitors of TF suppress tumor growth and angiogenesis 14 . PAR-1 and PAR-2 have also been implicated in angiogenesis 15, 16 , but in vivo data linking angiogenesis to PAR activation by TF-initiated coagulation remain sparse 17 . muscle cell actin (SMA; Fig. 1b) . We observed similar TF expression levels in sprouting TF∆CT and wild-type aortas (Fig. 1d) , indicating that loss of the TF cytoplasmic tail, rather than deregulated TF expression, caused accelerated endothelial cell sprouting in TF∆CT mice.
Because TF cytoplasmic domain signaling has been implicated in regulating VEGF expression by tumor cells 11 , we tested whether wildtype aortas show reduced sprouting because of a relative deficiency in VEGF. Supplementing serum with VEGF did not abolish the difference in sprouting from TF∆CT compared with wild-type aortas (Fig. 2a) . Aortas stimulated with VEGF in the absence of serum showed very limited sprouting, however, indicating that serum was required for accelerated angiogenesis from TF∆CT aortas (Fig. 2a) . Sprouting from wild-type aortas in the presence of TF∆CT mouse serum (serum swap) was not enhanced, indicating that TF expressed by TF∆CT vascular cells, rather than a serum factor or increased levels of circulating TF, confers the proangiogenic phenotype (Fig. 2a) .
TF-VIIa signaling accelerates angiogenesis in TF∆CT aortas
The serum dependence of the TF∆CT sprouting phenotype suggested that genetic ablation of the TF cytoplasmic tail may unmask coagulation factor-dependent proangiogenic activity. We therefore studied the inhibitory effects of blocking coagulation proteases in the aortic ring sprouting model (Fig. 2b) . Inhibition of thrombin by hirudin, as well as inactivation of Xa by nematode anticoagulant peptide-5 (NAP-5), had no effect on sprouting, thereby excluding contribution from proteases downstream in the coagulation cascade. Active site-inhibited VIIa (VIIai), a high-affinity competitive antagonist that blocks TF-VIIa complex formation, as well as NAP-c2, which inhibits TF-VIIa by forming a trapped TF-VIIa-Xa complex, reversed the TF∆CT sprouting phenotype but did not influence sprouting from wild-type aortas. The combination of NAP-c2 and NAP-5 had an effect similar to that of NAP-5 alone, excluding the possibility that Xa, which can signal in the NAP-c2-trapped TF-VIIa-Xa complex 10 , unexpectedly suppressed the TF∆CT phenotype. These results suggest that the TF cytoplasmic domain negatively regulates TF-VIIa protease signaling.
To directly analyze the role of VIIa in angiogenesis, we replaced serum with VIIa in the aortic ring model. VIIa inefficiently induced sprouting from both wild-type and TF∆CT aortas (Fig. 2c) . Because endothelial cell sprouting is typically dependent on growth factor signaling, we further characterized sprouting from TF∆CT aortas in the presence of the defined proangiogenic growth factors VEGF, PDGF-AA, PDGF-BB and basic fibroblast growth factor (FGF). None of these factors promoted substantial sprouting, which is consistent with previous data 18 , and the proangiogenic phenotype of TF∆CT was not apparent in the presence of any of the growth factors alone. However, combining VIIa with PDGF-BB selectively recapitulated the proangiogenic phenotype of TF∆CT observed under serum conditions (Fig. 2c) . There was no evidence for an additive effect of PDGF-BB and VIIa on sprouting from wild-type aortas, as described for fibroblast migration 19 . PDGF-AA is a selective agonist for PDGF receptor-α but cannot activate PDGF receptor-β. Because VIIa enhanced angiogenesis in the presence of PDGF-BB, but not PDGF-AA, TF-VIIa signaling seems to synergize with PDGF receptor-β signaling when negative regulatory control by the TF cytoplasmic domain is lost.
TF-VIIa signaling cross-talk with PAR-2 regulates angiogenesis
Because PAR-2 is the primary target for TF-VIIa signaling, we hypothesized that TF-VIIa-dependent PAR-2 activation synergizes with PDGF-BB to accelerate angiogenesis in TF∆CT mice. We used a genetic approach to test our hypothesis. Aortic ring sprouting in TF∆CT mice that are also deficient in PAR-2 reverted to wild-type levels (Fig. 2d,e) , indicating that loss of the TF cytoplasmic domain leads to PAR-2-dependent accelerated angiogenesis. No alterations in angiogenesis were evident upon deletion of PAR2 alone, suggesting that the TF cytoplasmic tail is highly efficient in suppressing the proangiogenic effects of PAR-2. This was also supported by the finding that TF-directed inhibitors (VIIai and NAP-c2) did not reduce sprouting from wild-type aortas (Fig. 2b) . (Fig. 3a) . Colocalization of human TF with CD31 provided evidence for adenoviral transduction of endothelial cells. Western blot analysis of human TF in extracts from aortic ring assays confirmed equal expression levels of both forms of TF (Fig. 3b) . At a higher dose of virus, human TF(1-263) suppressed sprouting from both wild-type and TF∆CT aortas, whereas TF∆CT sprouting was selectively reversed to wild-type levels by a lower viral dose (Fig. 3c) . In all cases, truncated human TF(1-243) had no effect, showing that suppression is dependent on the TF cytoplasmic tail (Fig. 3c) . These data support the concept that, when introduced at the appropriate level, the TF cytoplasmic domain can restore negative regulatory control of PAR-2 signaling in angiogenesis.
To gain further insight into the mechanism by which the TF cytoplasmic domain suppresses PAR-2 signaling in angiogenesis, we tested whether the reversal of the proangiogenic phenotype of TF∆CT aortas requires signaling and extracellular protease assembly with the introduced human TF. Blockade of the extracellular domain of TF(1-263) with human TF-specific monoclonal antibodies prevented the reversal of the enhanced sprouting phenotype of TF∆CT mice (Fig. 3d) . The involvement of PAR-2 was addressed based on the finding that expression of high levels of human TF(1-263) suppressed sprouting from wild-type aortas. An equivalent virus dose did not reduce sprouting from PAR-2-deficient aortas, indicating that the suppressive function of the TF cytoplasmic domain requires PAR-2 expression (Fig. 3d) . Collectively, these data show that negative regulatory control of angiogenesis by the TF cytoplasmic domain occurs specifically in the context of PAR-2 signaling.
The TF cytoplasmic domain regulates physiological angiogenesis
To further address the role of the TF cytoplasmic domain in vivo, we characterized physiological angiogenesis in the neonatal retina, which develops a vascular network emanating from the optic disc in a stereotypical manner 20 . In neonatal mice, the diameter of the superficial vascular plexus of TF∆CT mice was twice that of wild-type mice, indicating that the TF cytoplasmic tail negatively regulates in vivo angiogenesis during postnatal development (Fig. 4a) . The extent of vascularization in newborn TF∆CT retinas was comparable to that of 2-d-old (P2) wild-type retinas (Fig. 4b) . Consistent with the data from the aortic ring assay, retinas from neonatal PAR-2-deficient and TF∆CT PAR-2-deficient mice showed age-appropriate vascularization (Fig. 4a) . The evaluation of at least ten retinas, derived from at least three different pregnancies for each genotype, confirmed the consistency of the observed phenotype of TF∆CT mice and the consistency of its reversal by concomitant deletion of PAR-2 (Fig. 4c) .
Vascular cell-specific localization of TF in TF∆CT retinas was difficult to evaluate because of the prominent expression of TF by astrocytes, an established TF-expressing cell type in the CNS 21 , as well as potential TF expression by the underlying nerve fibers. Glial fibrillary acidic protein (GFAP) staining of astrocytes revealed that astrocytes extended to the periphery of retinas from both wild-type and TF∆CT newborn mice, with no apparent difference in staining patterns (Fig. 5a) . This result argues that vascular development did not indirectly follow accelerated developmental astrocyte migration in TF∆CT retinas. Vascular apoptosis is infrequently observed in wild-type mice at this stage of development 22 , and protection from apoptosis is therefore an unlikely cause for accelerated angiogenesis in TF∆CT mice. Enhanced vascular development may result from increased cell proliferation, but proliferating vascular cells as assessed by Ki-67 staining are present in comparable numbers in both newborn TF∆CT and P2 wild-type retinas (Fig. 5b,c) . While the degree of peripheral vascular extension was comparable between P0 TF∆CT and P2 wild-type retinas, the degree of arborization was more pronounced in P2 wild-type vascular plexus (Fig. 4a,b) . This may reflect enhanced TF∆CT endothelial cell migration, consistent with the scaffolding function of PAR-2 that localizes the MAP kinase pathway at the leading edge of migrating cells 23 . TF is expressed in angiogenic endothelial cells associated with malignant breast tumors 13 , and in vitro studies have shown direct effects of PDGF-BB on primary endothelial cell migration and cord or tube formation through activation of PDGF receptor-β, which is detectable on capillary endothelial cells in vivo 24, 25 .
PDGF-BB signaling is also crucial to the recruitment and expansion of the mural cell and pericyte populations that stabilize and regulate remodeling of the vascular architecture [26] [27] [28] [29] nic vascular plexus in the yolk sac, with associated reduction in pericyte recruitment 30 . The close association between endothelial and mural cells during angiogenic sprouting makes it challenging to distinguish between autocrine effects of PDGF-BB on endothelial cells and secondary, paracrine effects on recruited mural cells 28, 29 . Using SMA staining as a pericyte-specific marker, we observed a similar staining pattern in the retinal vasculature of newborn TF∆CT and P2 wild-type mice (Fig. 5d) . Pericyte staining in each case extended to the tips of the sprouts (Fig. 5d) . The vascular plexus of P2 PAR-2-deficient or TF∆CT PAR-2-deficient mice were indistinguishable from those of P2 wildtype mice. These data show that pericyte recruitment is normal in PAR-2-deficient mice, and exclude the possibility that developmental vascular abnormalities of PAR-2 deficiency appear after day P0. Pericytes have important roles in remodeling the developing retinal vascular plexus. The equivalently expanded superficial vascular plexus of P6 TF∆CT and P8 wild-type retinas also showed comparable capillary network density, distribution of arteries and veins, and pattern of SMA staining (Fig. 5e) . These similarities at later stages of retinal vascularization argue against altered pericyte function. Accelerated vascular development in TF∆CT retinas persisted at least until day P6, when premature endothelial cell sprouting into the deeper layers of the retina was observed. Collectively, these data are consistent with a phenotype of accelerated endothelial cell migration in the development of the superficial vascular plexus in TF∆CT mice, rather than abnormal pericyte recruitment.
TF phosphorylation in neovascular eye disease
A role for TF in pathological angiogenesis is suggested by the association of TF with the endothelium in malignant breast cancer 13 . The TF cytoplasmic domain is typically unphosphorylated in endothelial cells 31 . We hypothesized that phosphorylation may release the negative regulatory effects of the TF cytoplasmic domain and thus promote pathological angiogenesis. To determine whether TF phosphorylation occurs in pathological angiogenesis, we analyzed specimens of neovascularized iris that were removed from diabetic patients. Indeed, staining with an antibody 31 that specifically recognizes TF phosphorylated at Ser258 identified TF cytoplasmic domain phosphorylation only at sites of neovascularization in specimens from six different patients (Fig. 6a-c) . TF phosphorylation in these pathological vessels colocalized with PAR-2 expression (Fig. 6a) , supporting a role for deregulated PAR-2 signaling during pathological neovascularization. Notably, phosphorylated TF and PAR-2 staining were not observed in control iris samples from a glaucoma patient with no history of diabetes or pathological neovascularization (Fig. 6d) . TF phosphorylation and PAR-2 upregulation were also observed specifically in neovessels in a retina obtained from a patient with diabetic retinopathy. Staining with an antibody to the TF extracellular domain revealed widespread expression of TF in glial and neuronal cell types, mature vessels and at sites of neovascularization (Fig. 6e) , although TF phosphorylation was observed only in dilated pathological vessels (Fig. 6e) . Staining of phosphorylated TF in pathological vessels was completely eliminated by competition with the antigenic peptide (Fig. 6a,f) . Nonspecific punctate staining that was incompletely competed by the immunogen was sometimes observed in the inner and outer limiting membranes, regions noted for nonspecific staining by different antibodies in retina specimens. TF phosphorylation was never observed on normal, mature retinal vessels, supporting a specific role for TF phosphorylation during pathological neovascularization. In serial sections, pronounced PAR-2 expression was observed specifically in the same vessels in which TF phosphorylation was observed (Fig. 6f) . To confirm that TF phosphorylation was specific to neovessels, we stained diabetic retinas for α v β 3 -integrin, a known marker of vascular proliferation (Fig. 6g,h ). Phosphorylated TF consistently colocalized with α v β 3 -positive neovessels, whereas normal retinal microvasculature, visualized by Ulex europaeus staining, was negative for both (Fig. 6g,h ).
DISCUSSION
Angiogenesis is an important component of the pathology observed in cancer, neovascular eye diseases and arthritis, where activation of coagulation is prevalent 1, 2 . In fact, coagulation may indirectly support angiogenesis in several ways, including generation of a transitional fibrin-rich extracellular matrix, release of pro-and antiangiogenic factors from activated platelets, and thrombin signaling through endothelial cell PAR-1 (ref. 17) . The results from this study provide new and unexpected insight into how coagulation signaling regulates angiogenesis, by demonstrating that PAR-2 signaling is tightly controlled by the TF cytoplasmic domain. Genetic deletion of the TF cytoplasmic domain results in accelerated physiological and pathological angiogenesis. Thus, loss of negative regulatory control by the TF cytoplasmic domain is a new pathway by which proangiogenic signaling of PAR-2 can be turned on. Whereas PAR-1 is constitutively expressed in endothelial cells, PAR-2 is specifically upregulated upon inflammatory cytokine stimulation, which also induces TF 32, 33 . In addition, TF expression is synergistically enhanced by concomitant VEGF signaling in endothelial cells 33 . Expression of TF and PAR-2, and the functionality of the TF-PAR-2 signaling pathway, thus critically depend on the availability of both angiogenic growth factors and inflammatory cytokines. Inflammatory cytokine production by recruited monocytes and macrophages is recognized as being important for angiogenesis and collateral growth of vessels 34 . These adaptive processes share similarities with wound repair, which is typically associated with efforts by the innate immune system to clear pathogens from injured tissues. Accelerated angiogenesis during wound repair, when there is concomitant inflammation, may be the physiological function of the TF-PAR-2 signaling pathway and, thus, may explain the evolutionary conservation of the TF cytoplasmic domain structure and sites of post-translational modification in vertebrates.
Physiological response pathways frequently cause pathology when negative regulatory control mechanisms are lost. The TF cytoplasmic domain is targeted for post-translational Ser phosphorylation 31, 35, 36 through PKC-α-dependent pathways in endothelial cells 31 . TF is primarily unphosphorylated, and palmitoylation suppresses agonistinduced TF phosphorylation 31 . We have recently established that activation of PAR-2, but not PAR-1, leads to phosphorylation of the TF cytoplasmic domain in endothelial cells 37 . Thus, loss of palmitoylation 38 in conjunction with upregulation of PAR-2 determines the degree of phosphorylation of the TF cytoplasmic domain. This concept is supported by in vivo data from diabetic eye tissue; we observed a notable colocalization of upregulated PAR-2 with phosphorylated TF only in neovessels. Thus, phosphorylation of TF is the probable mechanism that switches off negative regulatory control to promote pathological PAR-2-dependent angiogenesis. TF-PAR-2 signaling selectively synergized with PDGF-BB, but not VEGF, basic FGF or PDGF-AA, in TF∆CT aortas. PDGF-BB is readily available, either by release from activated platelets in the context of local coagulation, or by synthesis from sprouting endothelial cells. Although VEGF-targeted antiangiogenic therapy seems efficacious in certain diseases, additional benefit may be obtained from combination therapy with molecules that target alternative and cooperative pathways. Inhibition of PDGF receptors, for example, has synergistic benefit in combination with VEGF-directed approaches 39 . Because PDGF-BB signaling is crucial in stabilizing pericyte recruitment and mature vessel architecture 26, 27 , generalized PDGF receptor blockade has obvious limitations. For example, reduced vascular pericyte density as a result of endothelium-specific PDGF-BB ablation causes microvascular angiopathy in mice 40 . It may be possible to target deregulated TF cytoplasmic domain signaling to suppress pathological PAR-2-and PDGF-dependent angiogenesis without interfering with the physiological vascular functions of PDGF.
METHODS
Mouse strains and reagents. TF∆CT mice, which lack the 18 C-terminal residues of the TF cytoplasmic domain 41 , and PAR-2-deficient mice 42 (provided by P. Andrade-Gordon, Johnson & Johnson Pharmaceutical Research & Development) were backcrossed to yield >90% homogeneity with the C57BL/6 genetic background. TF∆CT PAR-2-deficient double mutants were generated by interbreeding after five generations of backcrossing. Reagents were obtained from the following sources: Matrigel, Becton & Dickinson; endothelial cell growth medium, Clonetics; DMEM, GIBCO; growth factors, R&D Systems; TOPRO and isolectin Griffonia simplicifolia, Molecular Probes; antibody to CD31, Santa Cruz; antibodies to SMA and GFAP, Sigma; and antibody to Ki-67, NOVO Laboratories. Goat antibody and monoclonal antibodies to TF, VIIai, hirudin and VIIa were previously described 10 . NAP-c2 and NAP-5 were provided by G. Vlasuk (Corvas International). Adenoviral constructs of human TF(1-263) and human TF(1-243) were previously described 31 , and Ad5 serotype vectors coexpressing GFP were similarly generated.
Tumor growth. All animal experiments were approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute. T241 fibrosarcoma cells (4 × 10 5 ) were injected subcutaneously into wild-type and TF∆CT mice aged 7-9 weeks and having >97% C57BL/6 genetic background. Tumor volumes and final weights were determined on day 14, and tumors were embedded in OCT. Ten-micron cryosections were fixed with acetone and stained for CD31, and vessel density per microscopic field was determined by fluorescence microscopy from six to eight sections of two tumors each from wild-type and TF∆CT mice.
Angiogenesis assays. The ex vivo angiogenesis assay was adopted from the rat aortic sprouting model 18, 43 . Thoracic aortas from 8-to 11-week-old wild-type, TF∆CT, PAR-2-deficient and TF∆CT PAR-2-deficient mice of either sex were embedded in Matrigel. Embedded aortas were overlaid with endothelial cell growth medium supplemented with 5% serum and containing growth factors or inhibitors at the following concentrations: VEGF, basic FGF and PDGF, 20 ng/ml; hirudin, 500 nM; VIIai, 100 nM; NAP-c2, 200 nM; NAP-5, 1 µM; and VIIa, 50 nM. In most cases, the number of aortic sprouts was determined on days 3 and 4, without knowledge of the genotype. Aortic ring RNA was isolated by TRIzol (Invitrogen) extraction using standard procedures, digested with DNase I and subjected to RT-PCR for β-actin and TF. Aortic pieces were transduced with adenoviral constructs expressing full-length human TF(1-263) or truncated human TF(1-243) in serum-free DMEM for 20-24 h, before embedding into the sprouting assay. Experiments used two different viral doses, referred to as high (1.1 × 10 10 virus particles/ml) and low (5 × 10 9 particles/ml). For confocal fluorescence microscopy, aortic pieces with a minimum of surrounding Matrigel were fixed with 4% paraformaldehyde and methanol, incubated with primary and secondary antibodies (24 h each) and mounted in anti-fade medium (Vector Laboratories). Alternatively, cryosections of OCT-embedded aortas were fixed with acetone and stained as above.
To evaluate neonatal angiogenesis, retina whole mounts were prepared and angiogenesis was quantified as described 20 . The numbers of retinas and litters used for each genotype were as follows: wild type, 20 retinas from six litters; TF∆CT, 24 retinas from five litters; PAR-2-deficient, 10 retinas from three litters; and TF∆CT PAR-2 deficient, 16 retinas from four litters. Dissected retinas were fixed in 4% paraformaldehyde and methanol, incubated in primary antibody or fluorescence-conjugated isolectin Griffonia simplicifolia overnight, incubated with secondary antibody and mounted. All retinas were imaged using the same magnification, resolution and intensity parameters. Images were assembled as single-retina montages, and the diameter of vascularization was quantified using LaserPix software (BioRad; eight diameter measurements taken at one, two, three, four, five and six o'clock, and two random intermediate positions). Total numbers of vascular-related Ki-67 + nuclei were determined by focusing within the vascular plane, which eliminates proliferating neuronal cells from the count.
Analysis of ocular specimens. All experiments using human tissues were performed according to protocols approved by the Human Subjects Committee of the Scripps Office for the Protection of Human Subjects and with permission from informed patients. Specimens of iris, already scheduled to be removed for clinical reasons, were immediately immersed in 20% sucrose at 4 °C before preparation of frozen sections. The specimen of neovascular retina was obtained from the San Diego Eye Bank. This eye was obtained from a patient clinically diagnosed with diabetic retinopathy for over 25 years. After dissection, the retina was fixed with 4% PFA overnight at 4 °C, followed by cryoprotection in 20% sucrose and cryosectioning. Frozen sections were processed for primary antibodies and detected with secondary antibodies conjugated either to Alexa 488, Alexa 568 or Alexa 633 (Molecular Probes) for confocal microscopy. We used mouse antibodies to CD31 (Biocare Medical; 1:50) and α v β 3 -integrin (LM609; 1:500); rhodamine-conjugated Ulex europaeus agglutinin-1 (Vector Laboratories, 1:1,000); and rabbit antibodies to the TF extracellular domain (R4563; 25 µg/ml), Ser258-phosphorylated TF cytoplasmic domain (R6936; 25 µg/ml) 31 and PAR-2 (R6797; 25 µg/ml) 6 . The peptides used as immunogens for R6936 and R6797 were added at 50 µg/ml to confirm specificity.
